Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770493 | 0.81 | KDM4E (0.53) | RAB9AALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL772325 | 0.81 | RAB9A (0.53) | TDP1RAB9ANPC1ALDH1A1HPGD | |
| SCHEMBL771597 | 0.80 | ALDH1A1 (0.49) | ALDH1A1HPGDSMN1; SMN2PKMKMT2A | |
| SCHEMBL770994 | 0.78 | RAB9A (0.55) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL771711 | 0.77 | LMNA (0.49) | ALDH1A1HPGDSMN1; SMN2PKMKMT2A | |
| SCHEMBL770891 | 0.76 | KMT2A (0.49) | ALDH1A1HPGDPKMKMT2AL3MBTL1 | |
| SCHEMBL770442 | 0.75 | HSD11B1 (0.42) | KMT2A | |
| SCHEMBL772462 | 0.75 | ALDH1A1 (0.53) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL770516 | 0.74 | SMN1; SMN2 (0.49) | RAB9ANPC1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL771920 | 0.73 | ITGB3 (0.48) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | TDP1 135/4885RAB9A 2187/4885NPC1 97/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | TDP1 134/4885RAB9A 2217/4885NPC1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.